Histrelin Peptide: Supprelin LA, Vantas, Uses and Safety Limits
Histrelin peptide guide covering GnRH agonist biology, the Supprelin LA and Vantas implant labels, precocious puberty and prostate cancer evidence, and safety limits.
Histrelin is a peptide medicine with a very different evidence profile from research-market hormone peptides. It is a synthetic nonapeptide analog of gonadotropin-releasing hormone, often called a GnRH agonist, and it is unusual in one respect: it is delivered as a small subcutaneous implant that releases drug continuously for about twelve months rather than as a repeated injection.
The two products that defined histrelin in the United States are Supprelin LA, a pediatric implant for central precocious puberty, and Vantas, an implant once used for advanced prostate cancer. They share the same active peptide and the same 50 mg implant format, but the patient population, indication and safety context differ sharply. A pediatric puberty implant is not the same thing as a prostate cancer implant, and neither should be reduced to a generic "hormone peptide" protocol.
For related endocrine context, compare this guide with leuprolide, gonadorelin, kisspeptin, oxytocin and what peptides are. Because histrelin is an implant rather than a syringe peptide, the peptide half-life guide is more relevant to it than general injection technique, which it does not use at all.
This guide is educational and not medical advice. Histrelin is a prescription implant placed and removed by a clinician. It should be started, monitored, changed or stopped only through qualified medical care.
Histrelin At A Glance
| Question | Evidence-aware answer |
|---|---|
| What is it? | A synthetic GnRH agonist nonapeptide delivered as a subcutaneous implant. |
| Common US brands | Supprelin LA (pediatric) and Vantas (prostate cancer, discontinued in 2021). |
| Main effect | Downregulates pituitary LH and FSH signaling after an initial stimulation phase. |
| Format | A 50 mg histrelin acetate implant placed in the inner upper arm for about 12 months. |
| Main clinical areas | Central precocious puberty (Supprelin LA) and advanced prostate cancer (Vantas). |
| Evidence type | FDA labels, pharmacokinetic data, and phase 3 implant trials. |
| Main safety frame | Hormone flare first, then sex-steroid suppression with product-specific monitoring. |
How A GnRH Agonist Implant Lowers Hormones
Native GnRH is released in pulses from the hypothalamus. Those pulses tell the pituitary to release luteinizing hormone, or LH, and follicle-stimulating hormone, or FSH. LH and FSH in turn regulate testosterone, estradiol, ovulation, puberty timing and related reproductive-hormone pathways.
Histrelin is an agonist at the GnRH receptor on pituitary gonadotrophs. That sounds like it should stimulate the axis, and at first it does. According to the Supprelin LA prescribing information, continuous administration produces an initial transient rise in gonadotropins and sex steroids, followed by down-regulation of GnRH receptors and a sustained decrease in LH, FSH and sex steroid production.
The implant format matters here. Rather than dosing peaks and troughs, the hydrogel reservoir releases histrelin at a near-constant rate. The Supprelin LA label describes delivery of roughly 65 mcg of histrelin acetate per day over twelve months; the Vantas label described roughly 50 mcg per day from a 50 mg implant delivering about 41 mg of histrelin. That steady exposure is what keeps the pituitary in a downregulated state for the life of the implant.
One detail surprises people: the peptide itself clears quickly. Pharmacokinetic data cited in the labels report an apparent clearance of about 179 mL/min and a terminal half-life near 3.9 hours after a subcutaneous bolus. The long duration of effect comes from the implant continuously replacing what the body clears, not from a long intrinsic half-life. When the implant is removed, circulating histrelin falls quickly and the axis can recover.
Product-Specific Uses
Histrelin's two implant products are not interchangeable just because they contain the same peptide.
| Product context | What the source supports | Important limit |
|---|---|---|
| Supprelin LA label | Central precocious puberty in children, one 50 mg implant for 12 months. | Pubertal signs can briefly increase early; psychiatric events, convulsions and pseudotumor cerebri are labeled warnings. |
| Vantas label | Palliative treatment of advanced prostate cancer, one 50 mg implant for 12 months. | Vantas was discontinued by the manufacturer in 2021 and is no longer marketed in the US. |
| Initial US approval | Histrelin acetate was first US-approved in 1991. | The implant products came later: Vantas in 2004 and Supprelin LA in 2007. |
| MedlinePlus patient information | Describes the implant placement, removal and monitoring expectations. | Patient summaries are broad and do not replace exact product labeling. |
This is why a histrelin search can feel fragmented. The peptide is the same, but the implant a pediatric endocrinologist places for early puberty is governed by a different label than the implant a urologist once placed for prostate cancer.
Central Precocious Puberty Evidence
Central precocious puberty, or CPP, is early activation of the hypothalamic-pituitary-gonadal axis, generally defined as secondary sexual characteristics before age 8 in girls and 9 in boys. Untreated, it can advance bone age and reduce final adult height. A long-acting GnRH agonist suppresses pubertal progression while treatment is active.
The pivotal evidence is a phase 3, open-label, multicenter trial published in the Journal of Clinical Endocrinology and Metabolism. In children given a single 50 mg histrelin implant, peak stimulated LH fell sharply within one month and suppression was maintained across the year of treatment, with good tolerability. Follow-up reports, including a published two-year experience, found that a single implant could maintain suppression beyond the initial twelve months in many children, which influenced how clinicians time implant exchanges.
The label adds practical safety context. Supprelin LA warns that gonadotropins and sex steroids can rise early, so pubertal signs may temporarily increase, and it discusses psychiatric events, convulsions, pseudotumor cerebri and frequent implant-site reactions. These warnings do not mean histrelin is inappropriate in CPP. They mean the benefit-risk decision is medical, age-specific and monitoring-dependent.
Advanced Prostate Cancer Evidence
In advanced prostate cancer, the goal of a GnRH agonist is to suppress testosterone into the castrate range as part of androgen deprivation therapy. A phase 3 study of the histrelin implant published in the Journal of Urology reported that of patients with week-4 testosterone available, essentially all achieved castrate testosterone, and suppression was maintained through 52 weeks in more than 99 percent. PSA fell substantially from baseline, and no testosterone or LH surge was observed on reimplantation. A separate long-term report described durable tolerability and castration with repeated yearly implants.
This is meaningful efficacy, but two caveats anchor it. First, GnRH agonist therapy carries an early flare risk: testosterone can rise before it falls, which can transiently worsen symptoms in men with significant disease burden. Second, Vantas was discontinued by its manufacturer in 2021 and is no longer available in the United States, so the prostate cancer data are best read as historical evidence for the histrelin implant rather than a description of a currently marketed product.
Safety Limits
Histrelin safety follows from its mechanism and from the product labels. It first stimulates and then suppresses hormone signaling, and both phases matter. Because it is an implant, it also carries device-specific risks.
| Safety issue | Why it matters |
|---|---|
| Early hormone flare | Sex steroids can rise in the first weeks, briefly worsening symptoms or pubertal signs. |
| Implant-site reactions | The Supprelin LA label reports site reactions in roughly half of patients; bruising, pain or, rarely, implant breakage or extrusion can occur. |
| Psychiatric and emotional events | Pediatric labeling discusses emotional lability such as crying, irritability and aggression. |
| Convulsions | Labels report seizures in patients with and without predisposing factors. |
| Pseudotumor cerebri | Idiopathic intracranial hypertension has been reported and warrants monitoring for headache and visual changes. |
| Bone-density loss | Sustained sex-steroid suppression can reduce bone density with longer use. |
| Metabolic and cardiovascular risk | Androgen deprivation in men is associated with metabolic and cardiovascular concerns. |
| Pregnancy harm | Histrelin can harm a fetus and is not for use during pregnancy. |
Histrelin can also cause hot flashes, fatigue, weight gain, headache, libido changes and, in men, testicular atrophy, depending on patient and indication.
How To Evaluate A Histrelin Claim
Ask six questions before trusting any histrelin claim.
First, which product is being discussed: Supprelin LA, Vantas or a generic histrelin implant? They share a peptide but not a label.
Second, what is the indication: central precocious puberty, advanced prostate cancer or something the label does not support?
Third, does the source acknowledge that this is an implant placed and removed by a clinician, not a self-injected peptide?
Fourth, does it mention the early flare? Unlike leuprolide discussions that often cover flare in detail, casual histrelin content frequently skips this core feature of GnRH agonist therapy.
Fifth, does it address implant-site reactions, psychiatric effects, seizures, pseudotumor cerebri, bone health or pregnancy risk where relevant?
Sixth, is it using prescription-label evidence to imply unregulated human use or a wellness "hormone balance" benefit? That is a red flag. Histrelin has no legitimate over-the-counter or research-market role.
Bottom Line
Histrelin is a real peptide medicine with strong, label-backed evidence in two specific hormone-suppression settings. As a 12-month subcutaneous implant, it can reliably suppress LH, FSH and sex steroids after an initial stimulation phase, which made it effective for central precocious puberty under the Supprelin LA label and for advanced prostate cancer under the now-discontinued Vantas label.
The same mechanism creates limits. Histrelin is not a casual hormone peptide, not a general wellness tool and not a product to interpret without the exact label. Implant placement and removal, early flare, site reactions, psychiatric and seizure monitoring, bone health and pregnancy avoidance are central to its safe use, and they are all medical decisions.
References
DailyMed. Supprelin LA (histrelin acetate) implant prescribing information.
US Food and Drug Administration. Vantas (histrelin implant) prescribing information.
US FDA, Drugs@FDA. Drug approval package: Vantas (histrelin implant), NDA 021732.
MedlinePlus. Histrelin Implant drug information.
Eugster EA, et al. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial. J Clin Endocrinol Metab. 2007.
Rahhal S, et al. Experience with the once-yearly histrelin (GnRHa) subcutaneous implant in the treatment of central precocious puberty.
Lewis KA, et al. A single histrelin implant is effective for 2 years for treatment of central precocious puberty.
Schlegel PN, et al. Efficacy and safety of histrelin subdermal implant in patients with advanced prostate cancer. J Urol. 2006.
Schlegel PN, et al. Long-term efficacy and tolerability of once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancer.
Chertin B, et al. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
Shore N, et al. Analysis of testosterone suppression in men receiving histrelin, a novel GnRH agonist for the treatment of prostate cancer.